AR101174A1 - Imidazopirazinas como inhibidores de lsd1 - Google Patents

Imidazopirazinas como inhibidores de lsd1

Info

Publication number
AR101174A1
AR101174A1 ARP150102197A ARP150102197A AR101174A1 AR 101174 A1 AR101174 A1 AR 101174A1 AR P150102197 A ARP150102197 A AR P150102197A AR P150102197 A ARP150102197 A AR P150102197A AR 101174 A1 AR101174 A1 AR 101174A1
Authority
AR
Argentina
Prior art keywords
nrc7rd7
alkyl
nrc7c
ora7
independently selected
Prior art date
Application number
ARP150102197A
Other languages
English (en)
Inventor
Sun Yaping
Li Jingwei
R Courter Joel
Zhuo Jincong
Zhang Colin
Yao Wenquing
Wang Xiaozhao
Lu Liang
He Chunhong
Wu Liangxing
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR101174A1 publication Critical patent/AR101174A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente se dirige a derivados de imidazo[1,2-a]pirazina que son inhibidores de LSD1 útiles en el tratamiento de enfermedades tales como cáncer. Reivindicación 1: Un compuesto de fórmula (1), o una de sus sales farmacéuticamente aceptables, caracterizado porque: el anillo A es arilo C₆₋₁₀ o heteroarilo de 5 - 10 miembros que comprende carbono y 1, 2, 3, ó 4 heteroátomos seleccionados de N, O, y S, donde dicho arilo C₆₋₁₀ y heteroarilo de 5 - 10 miembros están opcionalmente sustituidos con 1, 2, 3, ó 4 sustituyentes seleccionados de modo independiente de RA; el anillo B es arilo C₆₋₁₀; heteroarilo de 5 - 10 miembros que comprende carbono y 1, 2, 3 ó 4 heteroátomos seleccionados de N, O, y S; cicloalquilo C₃₋₁₀; o heterocicloalquilo de 4 - 10 miembros que comprende carbono y 1, 2, 3 ó 4 heteroátomos seleccionados de N, O, y S; donde dicho arilo C₆₋₁₀, heteroarilo de 5 - 10 miembros, cicloalquilo C₃₋₁₀, y heterocicloalquilo de 4 - 10 miembros están opcionalmente sustituidos con 1, 2, 3, ó 4 sustituyentes seleccionados de modo independiente de RB; R¹ es halo, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, Cy¹, CN, ORᵃ¹, SRᵃ¹, C(O)Rᵇ¹, C(O)NRᶜ¹Rᵈ¹, C(O)ORᵃ¹, OC(O)Rᵇ¹, OC(O)NRᶜ¹Rᵈ¹, NRᶜ¹Rᵈ¹, NRᶜ¹C(O)Rᵇ¹, NRᶜ¹C(O)ORᵃ¹, NRᶜ¹C(O)NRᶜ¹Rᵈ¹, C(=NRᵉ¹)Rᵇ¹, C(=NRᵉ¹)NRᶜ¹Rᵈ¹, NRᶜ¹C(=NRᵉ¹)NRᶜ¹Rᵈ¹, NRᶜ¹S(O)Rᵇ¹, NRᶜ¹S(O)₂Rᵇ¹, NRᶜ¹S(O)₂NRᶜ¹Rᵈ¹, S(O)Rᵇ¹, S(O)NRᶜ¹Rᵈ¹, S(O)₂Rᵇ¹, o S(O)₂NRᶜ¹Rᵈ¹; donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, y alquinilo C₂₋₆ están opcionalmente sustituidos con 1, 2, ó 3 sustituyentes seleccionados de modo independiente de Cy¹, halo, CN, OH, ORᵃ¹, SRᵃ¹, C(O)Rᵇ¹, C(O)NRᶜ¹Rᵈ¹, C(O)ORᵃ¹, OC(O)Rᵇ¹, OC(O)NRᶜ¹Rᵈ¹, NRᶜ¹Rᵈ¹, NRᶜ¹C(O)Rᵇ¹, NRᶜ¹C(O)ORᵃ¹, NRᶜ¹C(O)NRᶜ¹Rᵈ¹, C(=NRᵉ¹)Rᵇ¹, C(=NRᵉ¹)NRᶜ¹Rᵈ¹, NRᶜ¹C(=NRᵉ¹)NRᶜ¹Rᵈ¹, NRᶜ¹S(O)Rᵇ¹, NRᶜ¹S(O)₂Rᵇ¹, NRᶜ¹S(O)₂NRᶜ¹Rᵈ¹, S(O)Rᵇ¹, S(O)NRᶜ¹Rᵈ¹, S(O)₂Rᵇ¹, y S(O)₂NRᶜ¹Rᵈ¹; R² y R³ se seleccionan de modo independiente de H, halo, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, Cy², CN, ORᵃ², SRᵃ², C(O)Rᵇ², C(O)NRᶜ²Rᵈ², C(O)ORᵃ², OC(O)Rᵇ², OC(O)NRᶜ²Rᵈ², NRᶜ²Rᵈ², NRᶜ²C(O)Rᵇ², NRᶜ²C(O)ORᵃ², NRᶜ²C(O)NRᶜ²Rᵈ², C(=NRᵉ²)Rᵇ², C(=NRᵉ²)NRᶜ²Rᵈ², NRᶜ²C(=NRᵉ²)NRᶜ²Rᵈ², NRᶜ²S(O)Rᵇ², NRᶜ²S(O)₂Rᵇ², NRᶜ²S(O)₂NRᶜ²Rᵈ², S(O)Rᵇ², S(O)NRᶜ²Rᵈ², S(O)₂Rᵇ², y S(O)₂NRᶜ²Rᵈ²; donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, y alquinilo C₂₋₆ están opcionalmente sustituidos con 1, 2, ó 3 sustituyentes seleccionados de modo independiente de Cy², halo, CN, ORᵃ², SRᵃ², C(O)Rᵇ², C(O)NRᶜ²Rᵈ², C(O)ORᵃ², OC(O)Rᵇ², OC(O)NRᶜ²Rᵈ², NRᶜ²Rᵈ², NRᶜ²C(O)Rᵇ², NRᶜ²C(O)ORᵃ², NRᶜ²C(O)NRᶜ²Rᵈ², C(=NRᵉ²)Rᵇ², C(=NRᵉ²)NRᶜ²Rᵈ², NRᶜ²C(=NRᵉ²)NRᶜ²Rᵈ², NRᶜ²S(O)Rᵇ², NRᶜ²S(O)₂Rᵇ², NRᶜ²S(O)₂NRᶜ²Rᵈ², S(O)Rᵇ², S(O)NRᶜ²Rᵈ², S(O)₂Rᵇ², y S(O)₂NRᶜ²Rᵈ²; cada RA se selecciona de modo independiente de halo, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, CN, NO₂, ORᵃ⁴, SRᵃ⁴, C(O)Rᵇ⁴, C(O)NRᶜ⁴Rᵈ⁴, C(O)ORᵃ⁴, OC(O)Rᵇ⁴, OC(O)NRᶜ⁴Rᵈ⁴, NRᶜ⁴Rᵈ⁴, NRᶜ⁴C(O)Rᵇ⁴, NRᶜ⁴C(O)ORᵃ⁴, NRᶜ⁴C(O)NRᶜ⁴Rᵈ⁴, C(=NRᵉ⁴)Rᵇ⁴, C(=NRᵉ⁴)NRᶜ⁴Rᵈ⁴, NRᶜ⁴C(=NRᵉ⁴)NRᶜ⁴Rᵈ⁴, NRᶜ⁴S(O)Rᵇ⁴, NRᶜ⁴S(O)₂Rᵇ⁴, NRᶜ⁴S(O)₂NRᶜ⁴Rᵈ⁴, S(O)Rᵇ⁴, S(O)NRᶜ⁴Rᵈ⁴, S(O)₂Rᵇ⁴, y S(O)₂NRᶜ⁴Rᵈ⁴, donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, y alquinilo C₂₋₆ están opcionalmente sustituidos con 1, 2, ó 3, sustituyentes seleccionados de modo independiente de halo, haloalquilo C₁₋₆, CN, NO₂, ORᵃ⁴, SRᵃ⁴, C(O)Rᵇ⁴, C(O)NRᶜ⁴Rᵈ⁴, C(O)ORᵃ⁴, OC(O)Rᵇ⁴, OC(O)NRᶜ⁴Rᵈ⁴, NRᶜ⁴Rᵈ⁴, NRᶜ⁴C(O)Rᵇ⁴, NRᶜ⁴C(O)ORᵃ⁴, NRᶜ⁴C(O)NRᶜ⁴Rᵈ⁴, C(=NRᵉ⁴)Rᵇ⁴, C(=NRᵉ⁴)NRᶜ⁴Rᵈ⁴, NRᶜ⁴C(=NRᵉ⁴)NRᶜ⁴Rᵈ⁴, NRᶜ⁴S(O)Rᵇ⁴, NRᶜ⁴S(O)₂Rᵇ⁴, NRᶜ⁴S(O)₂NRᶜ⁴Rᵈ⁴, S(O)Rᵇ⁴, S(O)NRᶜ⁴Rᵈ⁴, S(O)₂Rᵇ⁴, y S(O)₂NRᶜ⁴Rᵈ⁴; cada RB se selecciona de modo independiente de Cy³, halo, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, CN, NO₂, ORᵃ⁵, SRᵃ⁵, C(O)Rᵇ⁵, C(O)NRᶜ⁵Rᵈ⁵, C(O)ORᵃ⁵, OC(O)Rᵇ⁵, OC(O)NRᶜ⁵Rᵈ⁵, NRᶜ⁵Rᵈ⁵, NRᶜ⁵C(O)Rᵇ⁵, NRᶜ⁵C(O)ORᵃ⁵, NRᶜ⁵C(O)NRᶜ⁵Rᵈ⁵, C(=NRᵉ⁵)Rᵇ⁵, C(=NRᵉ⁵)NRᶜ⁵Rᵈ⁵, NRᶜ⁵C(=NRᵉ⁵)NRᶜ⁵Rᵈ⁵, NRᶜ⁵S(O)Rᵇ⁵, NRᶜ⁵S(O)₂Rᵇ⁵, NRᶜ⁵S(O)₂NRᶜ⁵Rᵈ⁵, S(O)Rᵇ⁵, S(O)NRᶜ⁵Rᵈ⁵, S(O)₂Rᵇ⁵, y S(O)₂NRᶜ⁵Rᵈ⁵, donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, y alquinilo C₂₋₆ están opcionalmente sustituidos con 1, 2, ó 3 sustituyentes seleccionados de modo independiente de Cy³, halo, haloalquilo C₁₋₆, CN, NO₂, ORᵃ⁵, SRᵃ⁵, C(O)Rᵇ⁵, C(O)NRᶜ⁵Rᵈ⁵, C(O)ORᵃ⁵, OC(O)Rᵇ⁵, OC(O)NRᶜ⁵Rᵈ⁵, NRᶜ⁵Rᵈ⁵, NRᶜ⁵C(O)Rᵇ⁵, NRᶜ⁵C(O)ORᵃ⁵, NRᶜ⁵C(O)NRᶜ⁵Rᵈ⁵, C(=NRᵉ⁵)Rᵇ⁵, C(=NRᵉ⁵)NRᶜ⁵Rᵈ⁵, NRᶜ⁵C(=NRᵉ⁵)NRᶜ⁵Rᵈ⁵, NRᶜ⁵S(O)Rᵇ⁵, NRᶜ⁵S(O)₂Rᵇ⁵, NRᶜ⁵S(O)₂NRᶜ⁵Rᵈ⁵, S(O)Rᵇ⁵, S(O)NRᶜ⁵Rᵈ⁵, S(O)₂Rᵇ⁵, y S(O)₂NRᶜ⁵Rᵈ⁵; cada Cy¹, Cy², Cy³, y Cy⁴ se selecciona de modo independiente de arilo C₆₋₁₀, cicloalquilo C₃₋₁₀, heteroarilo de 5 - 10 miembros, y heterocicloalquilo de 4 - 10 miembros, cada uno de los cuales está opcionalmente sustituido con 1, 2, 3, ó 4 sustituyentes seleccionados de modo independiente de RCʸ; cada RCʸ se selecciona de modo independiente de halo, alquilo C₁₋₄, haloalquilo C₁₋₄, cianoalquilo C₁₋₄, alquenilo C₂₋₆, alquinilo C₂₋₆, fenilo, cicloalquilo C₃₋₇, heteroarilo de 5 - 6 miembros, heterocicloalquilo de 4 - 7 miembros, fenil-alquil C₁₋₄-, cicloalquil C₃₋₇-alquil C₁₋₄-, (heteroarilo de 5 - 6 miembros)-alquil C₁₋₄-, y (heterocicloalquilo de 4 - 7 miembros)-alquil C₁₋₄-, CN, NO₂, ORᵃ⁶, SRᵃ⁶, C(O)Rᵇ⁶, C(O)NRᶜ⁶Rᵈ⁶, C(O)ORᵃ⁶, OC(O)Rᵇ⁶, OC(O)NRᶜ⁶Rᵈ⁶, C(=NRᵉ⁶)NRᶜ⁶Rᵈ⁶, NRᶜ⁶C(=NRᵉ⁶)NRᶜ⁶Rᵈ⁶, NRᶜ⁶Rᵈ⁶, NRᶜ⁶C(O)Rᵇ⁶, NRᶜ⁶C(O)ORᵃ⁶, NRᶜ⁶C(O)NRᶜ⁶Rᵈ⁶, NRᶜ⁶S(O)Rᵇ⁶, NRᶜ⁶S(O)₂Rᵇ⁶, NRᶜ⁶S(O)₂NRᶜ⁶Rᵈ⁶, S(O)Rᵇ⁶, S(O)NRᶜ⁶Rᵈ⁶, S(O)₂Rᵇ⁶, y S(O)₂NRᶜ⁶Rᵈ⁶, donde dicho alquilo C₁₋₄, alquenilo C₂₋₆, alquinilo C₂₋₆, fenilo, cicloalquilo C₃₋₇, heteroarilo de 5 - 6 miembros, heterocicloalquilo de 4 - 7 miembros, fenil-alquil C₁₋₄-, cicloalquil C₃₋₇-alquil C₁₋₄-, (heteroarilo de 5 - 6 miembros)-alquil C₁₋₄-, y (heterocicloalquilo de 4 - 7 miembros)-alquil C₁₋₄- están opcionalmente sustituidos con 1, 2, ó 3 sustituyentes seleccionados de modo independiente de alquilo C₁₋₆, haloalquilo C₁₋₄, cianoalquilo C₁₋₆, halo, CN, NO₂, ORᵃ⁶, SRᵃ⁶, C(O)Rᵇ⁶, C(O)NRᶜ⁶Rᵈ⁶, C(O)ORᵃ⁶, OC(O)Rᵇ⁶, OC(O)NRᶜ⁶Rᵈ⁶, C(=NRᵉ⁶)NRᶜ⁶Rᵈ⁶, NRᶜ⁶C(=NRᵉ⁶)NRᶜ⁶Rᵈ⁶, NRᶜ⁶Rᵈ⁶, NRᶜ⁶C(O)Rᵇ⁶, NRᶜ⁶C(O)ORᵃ⁶, NRᶜ⁶C(O)NRᶜ⁶Rᵈ⁶, NRᶜ⁶S(O)Rᵇ⁶, NRᶜ⁶S(O)₂Rᵇ⁶, NRᶜ⁶S(O)₂NRᶜ⁶Rᵈ⁶, S(O)Rᵇ⁶, S(O)NRᶜ⁶Rᵈ⁶, S(O)₂Rᵇ⁶, y S(O)₂NRᶜ⁶Rᵈ⁶; cada Rᵃ¹ se selecciona de modo independiente de alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, y Cy⁴; donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, y alquinilo C₂₋₆ están opcionalmente sustituidos con 1, 2, ó 3 sustituyentes seleccionados de modo independiente de Cy⁴, halo, CN, ORᵃ³, SRᵃ³, C(O)Rᵇ³, C(O)NRᶜ³Rᵈ³, C(O)ORᵃ³, OC(O)Rᵇ³, OC(O)NRᶜ³Rᵈ³, NRᶜ³Rᵈ³, NRᶜ³C(O)Rᵇ³, NRᶜ³C(O)ORᵃ³, NRᶜ³C(O)NRᶜ³Rᵈ³, C(=NRᵉ³)Rᵇ³, C(=NRᵉ³)NRᶜ³Rᵈ³, NRᶜ³C(=NRᵉ³)NRᶜ³Rᵈ³, NRᶜ³S(O)Rᵇ³, NRᶜ³S(O)₂Rᵇ³, NRᶜ³S(O)₂NRᶜ³Rᵈ³, S(O)Rᵇ³, S(O)NRᶜ³Rᵈ³, S(O)₂Rᵇ³, y S(O)₂NRᶜ³Rᵈ³; cada Rᵇ¹, Rᶜ¹, y Rᵈ¹ se selecciona de modo independiente de H, alquilo C₁₋₆, haloalquilo C₁₋₄, alquenilo C₂₋₆, alquinilo C₂₋₆, arilo C₆₋₁₀, cicloalquilo C₃₋₁₀, heteroarilo de 5 - 10 miembros, heterocicloalquilo de 4 - 10 miembros, aril C₆₋₁₀-alquil C₁₋₄-, cicloalquil C₃₋₁₀-alquil C₁₋₄-, (heteroarilo de 5 - 10 miembros)-alquil C₁₋₄-, y (heterocicloalquilo de 4 - 10 miembros)-alquil C₁₋₄, donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, arilo C₆₋₁₀, cicloalquilo C₃₋₁₀, heteroarilo de 5 - 10 miembros, heterocicloalquilo de 4 - 10 miembros, aril C₆₋₁₀-alquil C₁₋₄, cicloalquil C₃₋₁₀-alquil C₁₋₄-, (heteroarilo de 5 - 10 miembros)-alquil C₁₋₄-, y (heterocicloalquilo de 4 - 10 miembros)-alquil C₁₋₄- están opcionalmente sustituidos con 1, 2, 3, 4, ó 5 sustituyentes seleccionados de modo independiente de alquilo C₁₋₄, haloalquilo C₁₋₄, cianoalquilo C₁₋₄, halo, CN, ORᵃ⁷, SRᵃ⁷, C(O)Rᵇ⁷, C(O)NRᶜ⁷Rᵈ⁷, C(O)ORᵃ⁷, OC(O)Rᵇ⁷, OC(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)Rᵇ⁷, NRᶜ⁷C(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)ORᵃ⁷, C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, S(O)Rᵇ⁷, S(O)NRᶜ⁷Rᵈ⁷, S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂NRᶜ⁷Rᵈ⁷, y S(O)₂NRᶜ⁷Rᵈ⁷; o Rᶜ¹ y Rᵈ¹ juntos con un átomo de N al que están unidos forman un grupo heterocicloalquilo de a 4, 5, 6, ó 7 miembros opcionalmente sustituido con 1, 2, ó 3 sustituyentes seleccionados de modo independiente de alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo de 4 - 7 miembros, arilo C₆₋₁₀, heteroarilo de 5 - 6 miembros, haloalquilo CN, halo, CN, ORᵃ⁷, SRᵃ⁷, C(O)Rᵇ⁷, C(O)NRᶜ⁷Rᵈ⁷, C(O)ORᵃ⁷, OC(O)Rᵇ⁷, OC(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)Rᵇ⁷, NRᶜ⁷C(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)ORᵃ⁷, C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, S(O)Rᵇ⁷, S(O)NRᶜ⁷Rᵈ⁷, S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂NRᶜ⁷Rᵈ⁷, y S(O)₂NRᶜ⁷Rᵈ⁷, donde dicho alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo de 4 - 7 miembros, arilo C₆₋₁₀, y heteroarilo de 5 - 6 miembros están opcionalmente sustituidos con 1, 2, ó 3 sustituyentes seleccionados de modo independiente de halo, alquilo C₁₋₄, haloalquilo C₁₋₄, cianoalquilo C₁₋₄, CN, ORᵃ⁷, SRᵃ⁷, C(O)Rᵇ⁷, C(O)NRᶜ⁷Rᵈ⁷, C(O)ORᵃ⁷, OC(O)Rᵇ⁷, OC(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)Rᵇ⁷, NRᶜ⁷C(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)ORᵃ⁷, C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, S(O)Rᵇ⁷, S(O)NRᶜ⁷Rᵈ⁷, S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂NRᶜ⁷Rᵈ⁷ y S(O)₂NRᶜ⁷Rᵈ⁷; cada Rᵃ², Rᵇ², Rᶜ², y Rᵈ² se selecciona de modo independiente de H, alquilo C₁₋₆, haloalquilo C₁₋₄, alquenilo C₂₋₆, alquinilo C₂₋₆, arilo C₆₋₁₀, cicloalquilo C₃₋₁₀, heteroarilo de 5 - 10 miembros, heterocicloalquilo de 4 - 10 miembros, aril C₆₋₁₀-alquil C₁₋₄, cicloalquil C₃₋₁₀-alquil C₁₋₄-, (heteroarilo de 5 - 10 miembros)-alquil C₁₋₄-, y (heterocicloalquilo de 4 - 10 miembros)-alquil C₁₋₄, donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, arilo C₆₋₁₀, cicloalquilo C₃₋₁₀, heteroarilo de 5 - 10 miembros, heterocicloalquilo de 4 - 10 miembros, aril C₆₋₁₀-alquil C₁₋₄-, cicloalquil C₃₋₁₀-alquil C₁₋₄, (heteroarilo de 5 - 10 miembros)-alquil C₁₋₄-, y (heterocicloalquilo de 4 - 10 miembros)-alquil C₁₋₄- están opcionalmente sustituidos con 1, 2, 3, 4, ó 5 sustituyentes seleccionados de modo independiente de alquilo C₁₋₄, haloalquilo C₁₋₄, cianoalquilo C₁₋₄, halo, CN, ORᵃ⁷, SRᵃ⁷, C(O)Rᵇ⁷, C(O)NRᶜ⁷Rᵈ⁷, C(O)ORᵃ⁷, OC(O)Rᵇ⁷, OC(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)Rᵇ⁷, NRᶜ⁷C(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)ORᵃ⁷, C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(=NRᵉ⁷)NRᶜ⁷Rᵇ⁷, S(O)Rᵇ⁷, S(O)NRᶜ⁷Rᵈ⁷, S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂NRᶜ⁷Rᵈ⁷, y S(O)₂NRᶜ⁷Rᵈ⁷; o Rᶜ² y Rᵈ² juntos con un átomo de N al que están unidos forman un grupo heterocicloalquilo de a 4, 5, 6, ó 7 miembros opcionalmente sustituido con 1, 2, ó 3 sustituyentes seleccionados de modo independiente de alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo de 4 - 7 miembros, fenilo, heteroarilo de 5 - 6 miembros, haloalquilo C₁₋₆, halo, CN, ORᵃ⁷, sRᵃ⁷, C(O)Rᵇ⁷, C(O)NRᶜ⁷Rᵈ⁷, C(O)ORᵃ⁷, OC(O)Rᵇ⁷, OC(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)Rᵇ⁷, NRᶜ⁷C(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)ORᵃ⁷, C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, S(O)Rᵇ⁷, S(O)NRᶜ⁷Rᵈ⁷, S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂NRᶜ⁷Rᵈ⁷, y S(O)₂NRᶜ⁷Rᵈ⁷, donde dicho alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo de 4 - 7 miembros, fenilo, y heteroarilo de 5 - 6 miembros están opcionalmente sustituidos con 1, 2, ó 3 sustituyentes seleccionados de modo independiente de halo, alquilo C₁₋₄, haloalquilo C₁₋₄, cianoalquilo C₁₋₄, CN, ORᵃ⁷, SRᵃ⁷, C(O)Rᵇ⁷, C(O)NRᶜ⁷Rᵈ⁷, C(O)ORᵃ⁷, OC(O)Rᵇ⁷, OC(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)Rᵇ⁷, NRᶜ⁷C(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)ORᵃ⁷, C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, S(O)Rᵇ⁷, -S(O)NRᶜ⁷Rᵈ⁷, S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂NRᶜ⁷Rᵈ⁷, y S(O)₂NRᶜ⁷Rᵈ⁷; cada Rᵃ³, Rᵇ³, Rᶜ³, y Rᵈ³ se selecciona de modo independiente de H, alquilo C₁₋₆, haloalquilo C₁₋₄, alquenilo C₂₋₆, alquinilo C₂₋₆, arilo C₆₋₁₀, cicloalquilo C₃₋₁₀, heteroarilo de 5 - 10 miembros, heterocicloalquilo de 4 - 10 miembros, aril C₆₋₁₀-alquil C₁₋₄-, cicloalquil C₃₋₁₀-alquil C₁₋₄-, (heteroarilo de 5 - 10 miembros)-alquil C₁₋₄-, y (heterocicloalquilo de 4 - 10 miembros)-alquil C₁₋₄-, donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, arilo C₆₋₁₀, cicloalquilo C₃₋₁₀, heteroarilo de 5 - 10 miembros, heterocicloalquilo de 4 - 10 miembros, aril C₆₋₁₀-alquil C₁₋₄-, cicloalquil C₃₋₁₀-alquil C₁₋₄-, (heteroarilo de 5 - 10 miembros)-alquil C₁₋₄-, y (heterocicloalquilo de 4 - 10 miembros)-alquil C₁₋₄- están opcionalmente sustituidos con 1, 2, 3, 4, ó 5 sustituyentes seleccionados de modo independiente de alquilo C₁₋₄, haloalquilo C₁₋₄, cianoalquilo CH, halo, CN, ORᵃ⁷, SRᵃ⁷, C(O)Rᵇ⁷, C(O)NRᶜ⁷Rᵈ⁷, C(O)ORᵃ⁷, OC(O)Rᵃ⁷, OC(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)Rᵇ⁷, NRᶜ⁷C(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)ORᵃ⁷, C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, S(O)Rᵇ⁷, S(O)NRᶜ⁷Rᵈ⁷, S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂NRᶜ⁷Rᵈ⁷, y S(O)₂NRᶜ⁷Rᵈ⁷; o Rᶜ³ y Rᵈ³ juntos con un átomo de N al que están unidos forman un grupo heterocicloalquilo de a 4, 5, 6, ó 7 miembros opcionalmente sustituido con 1, 2, ó 3 sustituyentes seleccionados de modo independiente de alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo de 4 - 7 miembros, fenilo, heteroarilo de 5 - 6 miembros, haloalquilo C₁₋₆, halo, CN, ORᵃ⁷, SRᵃ⁷, C(O)Rᵇ⁷, C(O)NRᶜ⁷Rᵈ⁷, C(O)ORᵃ⁷, OC(O)Rᵃ⁷, OC(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)Rᵇ⁷, NRᶜ⁷C(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)ORᵃ⁷, C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, S(O)Rᵇ⁷, S(O)NRᶜ⁷Rᵈ⁷, S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂NRᶜ⁷Rᵈ⁷, y S(O)₂NRᶜ⁷Rᵈ⁷, donde dicho alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo de 4 - 7 miembros, fenilo, y heteroarilo de 5 - 6 miembros están opcionalmente sustituidos con 1, 2, ó 3 sustituyentes seleccionados de modo independiente de halo, alquilo C₁₋₄, haloalquilo C₁₋₄, cianoalquilo C₁₋₄, CN, ORᵃ⁷, SRᵃ⁷, C(O)Rᵇ⁷, C(O)NRᶜ⁷Rᵈ⁷, C(O)ORᵃ⁷, OC(O)Rᵇ⁷, OC(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)Rᵇ⁷, NRᶜ⁷C(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)ORᵃ⁷, C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, S(O)Rᵇ⁷, S(O)NRᶜ⁷Rᵈ⁷, S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂NRᶜ⁷Rᵈ⁷, y S(O)₂NRᶜ⁷Rᵈ⁷; cada Rᵃ⁴, Rᵇ⁴, Rᶜ⁴, y Rᵈ⁴ se selecciona de modo independiente de H, alquilo C₁₋₆, haloalquilo C₁₋₄, alquenilo C₂₋₆, y alquinilo C₂₋₆, donde dicho alquilo C₁₋₄, alquenilo C₂₋₆, y alquinilo C₂₋₆ están opcionalmente sustituidos con 1, 2, 3, 4, ó 5 sustituyentes seleccionados de modo independiente de alquilo C₁₋₄, haloalquilo C₁₋₄, cianoalquilo C₁₋₄, halo, CN, ORᵃ⁷, SRᵃ⁷, C(O)Rᵇ⁷, C(O)NRᶜ⁷Rᵈ⁷, C(O)ORᵃ⁷, OC(O)Rᵇ⁷, OC(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)Rᵇ⁷, NRᶜ⁷C(O)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(O)ORᵃ⁷, C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, NRᶜ⁷C(=NRᵉ⁷)NRᶜ⁷Rᵈ⁷, S(O)Rᵇ⁷, S(O)NRᶜ⁷Rᵈ⁷, S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂Rᵇ⁷, NRᶜ⁷S(O)₂NRᶜ⁷Rᵈ⁷, y S(O)₂NRᶜ⁷Rᵈ⁷; o Rᶜ⁴ y Rᵈ⁴ juntos con un átomo de N al que están unidos forman un grupo heterocicloalquilo de a 4, 5, 6, ó 7 miembros opcionalmente sustituido con 1, 2, ó 3 sustituyentes seleccionados de modo independiente de alquilo C₁₋₆, haloalquilo C₁₋₆, halo, CN, ORᵃ⁷, SRᵃ⁷, C(O)Rᵇ⁷, C(O)NRᶜ⁷Rᵈ⁷, C(O)ORᵃ⁷, OC(O)Rᵇ⁷, OC(O)NRᶜ⁷Rᵈ⁷,
ARP150102197A 2014-07-10 2015-07-10 Imidazopirazinas como inhibidores de lsd1 AR101174A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462022913P 2014-07-10 2014-07-10

Publications (1)

Publication Number Publication Date
AR101174A1 true AR101174A1 (es) 2016-11-30

Family

ID=53682879

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102197A AR101174A1 (es) 2014-07-10 2015-07-10 Imidazopirazinas como inhibidores de lsd1

Country Status (4)

Country Link
US (3) US9695180B2 (es)
AR (1) AR101174A1 (es)
TW (1) TW201613925A (es)
WO (1) WO2016007736A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
HUE045725T2 (hu) 2014-02-13 2020-01-28 Incyte Corp Ciklopropilaminok mint LSD1 inhibitorok
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016073891A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
MX2017005940A (es) 2014-11-06 2018-01-11 Lysosomal Therapeutics Inc Pyrazolo [1, 5-a] pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos.
ES2958391T3 (es) 2014-11-06 2024-02-08 Bial R&D Invest S A Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
MA51438A (fr) 2015-04-03 2021-04-14 Incyte Corp Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
SG10201911989SA (en) 2015-06-12 2020-02-27 Oryzon Genomics Sa Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
MX2018001706A (es) 2015-08-12 2018-09-06 Incyte Corp Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
CN107174584B (zh) * 2016-03-12 2020-09-01 福建金乐医药科技有限公司 含哌嗪结构化合物在制备lsd1抑制剂中的应用
SG11201807965YA (en) 2016-03-15 2018-10-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
JP2019512546A (ja) 2016-03-16 2019-05-16 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ
JP7046827B2 (ja) 2016-04-06 2022-04-04 リソソーマル・セラピューティクス・インコーポレイテッド イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
CA3020310A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
JP7038063B2 (ja) 2016-04-06 2022-03-17 リソソーマル・セラピューティクス・インコーポレイテッド ピラゾロ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
CN109414410B (zh) 2016-04-22 2022-08-12 因赛特公司 Lsd1抑制剂的制剂
SG11201809693SA (en) 2016-05-05 2018-11-29 Lysosomal Therapeutics Inc SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192931A1 (en) * 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
WO2018106984A1 (en) 2016-12-09 2018-06-14 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
JP7352284B2 (ja) 2017-05-15 2023-09-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン ＬＳＤ－１インヒビターとしてのピロロ〔２，３－ｃ〕ピリジン及び関連類似体
AU2018294557A1 (en) * 2017-06-30 2020-01-02 Ryvu Therapeutics S.A. Imidazo(1,2-a)pyrazine modulators of the adenosine A2A receptor
WO2019025588A1 (en) 2017-08-03 2019-02-07 Oryzon Genomics, S.A. METHODS OF TREATING ALTERATIONS IN BEHAVIOR
TWI794294B (zh) 2017-09-13 2023-03-01 南韓商韓美藥品股份有限公司 吡唑衍生化合物及其用途
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
WO2019083971A1 (en) 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY
CN108220422B (zh) * 2018-01-05 2020-10-16 武汉惠康达科技有限公司 组蛋白去甲基化酶在筛选治疗脂肪肝及其相关疾病药物中的应用
US11944614B2 (en) 2018-05-15 2024-04-02 Regents Of The University Of Michigan Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
SG11202109159VA (en) 2019-03-20 2021-10-28 Oryzon Genomics Sa Methods of treating borderline personality disorder
EP3941465A1 (en) 2019-03-20 2022-01-26 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
WO2021094208A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
EP3964204A1 (en) 2020-09-08 2022-03-09 Université d'Aix-Marseille Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
EP4319732A1 (en) 2021-04-08 2024-02-14 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
GB202115017D0 (en) 2021-10-20 2021-12-01 Univ London Queen Mary Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
WO2023067058A1 (en) 2021-10-20 2023-04-27 Queen Mary University Of London Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors

Family Cites Families (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537889A (en) 1982-12-27 1985-08-27 Eli Lilly And Company Inotropic agents
US4625040A (en) 1984-09-24 1986-11-25 Pennwalt Corporation N-(phenyl) or N-(phenylcyclopropyl)-2,5-dihydro-2-oxo-4[(substituted phenyl)amino]-3-furancarboxamide derivatives
US4614810A (en) 1984-09-24 1986-09-30 Pennwalt Corporation 4,5-dihydro-4-oxo-2-[(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof
FR2607813B1 (fr) 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
FR2662163A1 (fr) 1990-05-16 1991-11-22 Lipha Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
ES2130269T3 (es) 1992-06-17 1999-07-01 Upjohn Co Oximas sustituidas con piridina, pirrolidina y azepina utiles como agentes contra la aterosclerosis y antihipercolesterolemicos.
DE4327027A1 (de) 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
FR2711993B1 (fr) * 1993-11-05 1995-12-01 Rhone Poulenc Rorer Sa Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
BR9814628A (pt) 1997-11-11 2001-11-27 Ono Pharmaceutical Co Derivados de pirazina fundidos
JP2000319277A (ja) 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
JP2000319278A (ja) 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
JP2001000687A (ja) 1999-06-23 2001-01-09 Ace Denken:Kk 遊技機
JP4041624B2 (ja) 1999-07-21 2008-01-30 三井化学株式会社 有機電界発光素子
JP2001057292A (ja) 1999-08-20 2001-02-27 Toray Ind Inc 発光素子
SE9903611D0 (sv) 1999-10-06 1999-10-06 Astra Ab Novel compounds III
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP4409680B2 (ja) 1999-10-18 2010-02-03 株式会社ヤクルト本社 三環性縮合イミダゾール誘導体
CA2407573C (en) 2000-04-27 2011-09-13 Yamanouchi Pharmaceutical Co. Ltd. Imidazopyridine derivatives
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
AU1560802A (en) 2000-06-28 2002-01-08 Smithkline Beecham Plc Wet milling process
US6589952B2 (en) 2000-07-14 2003-07-08 Bristol-Myers Squibb Pharma Company Imidazo[1,2-a]pyrazines for the treatment of neurological disorders
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
WO2002034748A1 (en) 2000-10-24 2002-05-02 Sankyo Company, Limited Imidazopyridine derivatives
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
ATE310740T1 (de) 2000-11-10 2005-12-15 Merck Sharp & Dohme Imidazotriazin-derivate als liganden für gaba- rezeptoren
EP1343785A2 (de) 2000-12-13 2003-09-17 Basf Aktiengesellschaft Verwendung von substituierten imidazoazinen, neue imidazoazine, verfahren zu deren herstellung, sowie sie enthaltende mittel
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
JP2005519915A (ja) 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
US7189723B2 (en) * 2003-02-10 2007-03-13 Cgi Pharmaceuticals, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
EP1604981A4 (en) 2003-03-14 2008-12-24 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
ATE455547T1 (de) 2003-04-11 2010-02-15 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen
ATE512957T1 (de) 2003-04-24 2011-07-15 Merck Sharp & Dohme Hemmer der akt aktivität
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
MXPA06000554A (es) 2003-07-14 2006-07-03 Arena Pharm Inc Derivados arilo y heteroarilo fusionados como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con los mismos.
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
WO2005025558A1 (en) 2003-09-12 2005-03-24 Applied Reserach Systems Ars Holding N.V. Sulfonamide derivatives for the treatment of diabetes
JP2005089352A (ja) 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
ATE369370T1 (de) 2003-10-10 2007-08-15 Pfizer Prod Inc Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
WO2005044793A2 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
WO2005063241A1 (ja) 2003-12-26 2005-07-14 Ono Pharmaceutical Co., Ltd. ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
US20070191395A1 (en) 2004-02-16 2007-08-16 Katsuhiro Kawakami Heterocyclic compounds having antifungal activity
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2006015263A2 (en) 2004-07-29 2006-02-09 Threshold Pharmaceuticals, Inc. Lonidamine analogs
MX2007001612A (es) 2004-08-18 2007-04-10 Upjohn Co Compuestos novedosos de triazolopiridina para el tratamiento de la inflamacion.
BRPI0516819A (pt) 2004-10-07 2008-09-23 Warner Lambert Co derivados de triazolopiridina e agentes antibacterianos
WO2006057946A2 (en) 2004-11-22 2006-06-01 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer agents and prodrugs thereof
AU2005311451A1 (en) 2004-12-01 2006-06-08 Merck Serono Sa [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
US20070293456A9 (en) 2004-12-30 2007-12-20 Anthony Hayford Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
EA012615B1 (ru) 2005-02-22 2009-10-30 Пфайзер Инк. Производные оксииндола в качестве агонистов 5-htрецептора
AR053712A1 (es) 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP1901748B1 (en) 2005-06-09 2010-09-08 Oncalis AG Angiogenesis inhibitors
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
WO2007028051A2 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
JP5031760B2 (ja) 2005-11-10 2012-09-26 シェーリング コーポレイション プロテインキナーゼインヒビターとしてのイミダゾピラジン
ATE537171T1 (de) 2005-12-27 2011-12-15 Hoffmann La Roche Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
WO2007074491A1 (en) 2005-12-28 2007-07-05 Universita Degli Studi Di Siena HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US8097617B2 (en) 2006-03-31 2012-01-17 Novartis Ag Organic compounds
AR061229A1 (es) 2006-06-06 2008-08-13 Schering Corp Imidazopirazinas como inhibidores de la proteina quinasa
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
JP2009534396A (ja) 2006-06-22 2009-09-24 マリンクロッド・インコーポレイテッド ピラジン誘導体および腎臓の監視におけるその使用
AU2007261397A1 (en) 2006-06-22 2007-12-27 Mallinckrodt Llc Pyrazine derivatives with extended conjugation and uses thereof
CN101506198A (zh) 2006-06-29 2009-08-12 先灵公司 取代的双环和三环凝血酶受体拮抗剂
WO2008005423A1 (en) 2006-07-03 2008-01-10 Cambrex Charles City, Inc. Improved method of making sufentanil
WO2008005908A2 (en) 2006-07-07 2008-01-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US20080021217A1 (en) 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
DE102006041292A1 (de) 2006-09-01 2008-03-06 Henkel Kgaa Wasserstoffperoxid-Aktivierung mit N-Heterocyclen
WO2008037607A1 (de) 2006-09-25 2008-04-03 Basf Se Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
CA2665195C (en) 2006-10-11 2011-08-09 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use thereof
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
NO346024B1 (no) 2006-11-22 2022-01-03 Incyte Holdings Corp Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
EP2086540B8 (en) 2006-12-01 2011-03-02 Galapagos N.V. Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
EP2118101B1 (en) 2007-03-09 2012-09-26 Probiodrug AG Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
JP2010523725A (ja) 2007-04-16 2010-07-15 レオ ファーマ アクティーゼルスカブ 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン
WO2008130951A1 (en) 2007-04-17 2008-10-30 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
US20110206607A1 (en) 2007-05-10 2011-08-25 Roger Olsson Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
JP5343845B2 (ja) 2007-05-21 2013-11-13 東レ株式会社 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
EP2167491A1 (en) 2007-06-08 2010-03-31 Abbott Laboratories 5-heteroaryl substituted indazoles as kinase inhibitors
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010529195A (ja) 2007-06-14 2010-08-26 シェーリング コーポレイション プロテインキナーゼの阻害剤としてのイミダゾピラジン
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
CN101808666A (zh) 2007-07-31 2010-08-18 先灵公司 作为抗癌治疗的抗有丝分裂剂和激光激酶抑制剂组合
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
JP2010535773A (ja) 2007-08-10 2010-11-25 グラクソスミスクライン エルエルシー ウイルス感染を治療するための窒素含有二環式化学物質
FR2920090A1 (fr) 2007-08-24 2009-02-27 Oreal Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine particuliere, un coupleur et un tensioactif particulier.
FR2920091A1 (fr) 2007-08-24 2009-02-27 Oreal Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine, un coupleur et un polyol particulier.
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
NZ585261A (en) 2007-10-11 2011-10-28 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
EP3733162A1 (en) 2007-10-12 2020-11-04 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
WO2009085230A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
AU2008343062B2 (en) 2007-12-19 2013-03-07 Genentech, Inc. 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
AU2009223640B2 (en) 2008-03-11 2013-07-04 Incyte Holdings Corporation Azetidine and cyclobutane derivatives as jak inhibitors
WO2009114180A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
EP2277881A4 (en) 2008-04-18 2011-09-07 Shionogi & Co HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
US8349210B2 (en) 2008-06-27 2013-01-08 Transitions Optical, Inc. Mesogenic stabilizers
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
JP2010070503A (ja) 2008-09-19 2010-04-02 Daiichi Sankyo Co Ltd 抗真菌作用２−アミノトリアゾロピリジン誘導体
US20120021519A1 (en) 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
ES2403633T3 (es) 2008-12-04 2013-05-20 Proximagen Limited Compuestos de imidazopiridina
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
EP2389362B1 (en) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
CA2750517A1 (en) 2009-02-04 2010-08-12 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2396331B1 (en) 2009-02-13 2013-10-16 Bayer Intellectual Property GmbH Fused pyrimidines as akt inhibitors
KR20100101054A (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2010108059A1 (en) 2009-03-20 2010-09-23 Incyte Corporation Substituted pyrimidine derivatives as antagonists of the histamine h4 receptor
CA2755132C (en) 2009-03-31 2018-02-13 Kissei Pharmaceutical Co., Ltd. Indolizine derivative and use thereof for medical purposes
BRPI1014572B8 (pt) 2009-04-16 2022-07-19 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazopirazinas para uso como inibidores de cinase
TWI461426B (zh) 2009-05-27 2014-11-21 Merck Sharp & Dohme （二氫）咪唑並異〔５，１－ａ〕喹啉類
AU2010258785A1 (en) 2009-06-10 2012-01-19 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
CA2766033C (en) 2009-06-25 2016-09-20 Alkermes, Inc. Prodrugs of nh-acidic compounds
PT2467141T (pt) 2009-08-17 2019-02-06 Intellikine Llc Compostos heterocíclicos e suas utilizações
US9708255B2 (en) 2009-08-18 2017-07-18 Robert A. Casero (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
EP2473495A1 (en) 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
WO2011035941A1 (en) 2009-09-25 2011-03-31 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
CA2793086C (en) 2010-03-18 2018-08-21 Institut Pasteur Korea Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections
US9468642B2 (en) 2010-03-18 2016-10-18 Bayer Intellectual Property Gmbh Imidazopyrazines
LT2552920T (lt) 2010-04-02 2017-06-12 Ogeda Sa Nauji nk-3 receptoriaus selektyvūs antagonistų junginiai, farmacinė kompozicija ir būdai, skirti naudoti nk-3 receptoriaus sąlygotų sutrikimų gydymui
CN102947265B (zh) 2010-04-19 2015-07-29 奥瑞泽恩基因组学股份有限公司 赖氨酸特异性脱甲基酶-1抑制剂及其应用
ES2564352T3 (es) 2010-04-20 2016-03-22 Università Degli Studi Di Roma "La Sapienza" Derivados de tranilcipromina como inhibidores de la histona-desmetilasa LSD1 y/o LSD2
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
SG185515A1 (en) 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
CN102295642B (zh) 2010-06-25 2016-04-06 中国人民解放军军事医学科学院毒物药物研究所 2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途
JP5858586B2 (ja) 2010-07-02 2016-02-10 ギリアード サイエンシーズ， インコーポレイテッド イオンチャネルモジュレーターとしての縮合複素環式化合物
CA2804845A1 (en) 2010-07-12 2012-01-19 Stuart Ince Substituted imidazo[1,2-a]pyrimidines and -pyridines
WO2012009475A1 (en) 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
CN103124724B (zh) 2010-07-29 2015-05-20 奥瑞泽恩基因组学股份有限公司 Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
WO2012034116A2 (en) 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
EP2623505B1 (en) 2010-09-29 2015-07-29 Kissei Pharmaceutical Co., Ltd. (aza)indolizine derivatives as xanthine oxidase inhibitors
US20130303545A1 (en) 2010-09-30 2013-11-14 Tamara Maes Cyclopropylamine derivatives useful as lsd1 inhibitors
US20120108500A1 (en) 2010-10-07 2012-05-03 Naoki Sakane Compositions and Methods for Modulating Immunodeficiency Virus Transcription
CN103188934B (zh) 2010-10-18 2015-08-26 纳幕尔杜邦公司 磺酰胺杀线虫剂
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
WO2012071469A2 (en) 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
UY33805A (es) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
CA2821817A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20140187548A1 (en) 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080236A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
ES2544609T3 (es) 2010-12-17 2015-09-02 Bayer Intellectual Property Gmbh Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
JP2014504604A (ja) 2011-01-21 2014-02-24 ザ ジェネラル ホスピタル コーポレイション 心血管疾患のための組成物および方法
EP2712316A1 (en) 2011-02-08 2014-04-02 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CA2831143C (en) 2011-03-25 2019-05-21 Glaxosmithkline Intellectual Property Development Limited Cyclopropylamines as lsd1 inhibitors
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
EP2750671A2 (en) 2011-05-19 2014-07-09 Oryzon Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
WO2012156531A2 (en) 2011-05-19 2012-11-22 Oryzon Genomics, S.A. Lysine demethylase inhibitors for inflammatory diseases or conditions
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201311149A (zh) 2011-06-24 2013-03-16 Ishihara Sangyo Kaisha 有害生物防治劑
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
KR20140052018A (ko) 2011-08-09 2014-05-02 다케다 야쿠힌 고교 가부시키가이샤 시클로프로판아민 화합물
SI2744330T1 (sl) 2011-08-15 2020-11-30 University Of Utah Research Foundation Substituirani (E)-N'-(1-feniletiliden) benzohidrazidni analogi kot inhibitorji histon-demetilaze
WO2013033688A1 (en) 2011-09-01 2013-03-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
US9273343B2 (en) 2011-09-02 2016-03-01 Promega Corporation Compounds and methods for assaying redox state of metabolically active cells and methods for measuring NAD(P)/NAD(P)H
JP2015531401A (ja) 2011-10-10 2015-11-02 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノン骨格を有するｐｄｅ９ｉ
EP4074695A1 (en) 2011-10-20 2022-10-19 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
RU2681211C2 (ru) 2011-10-20 2019-03-05 Оризон Дженомикс С.А. (гетеро)арилциклопропиламины в качестве ингибиторов lsd1
ITMI20111971A1 (it) 2011-10-28 2013-04-29 Mesogenics Srl Inibitori dell'enzima lsd-1 per l'induzione del differenziamento osteogenico
EP2785183B1 (en) 2011-11-14 2018-12-19 Merck Sharp & Dohme Corp. Triazolopyridinone pde10 inhibitors
WO2013085877A1 (en) 2011-12-05 2013-06-13 Brandeis University Treatment of amyloidosis by compounds that regulate retromer stabilization
EP2822948B1 (en) 2012-03-07 2016-04-06 Merck Patent GmbH Triazolopyrazine derivatives
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
CA2886187C (en) 2012-09-28 2020-04-14 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
CA2887203A1 (en) 2012-10-05 2014-04-10 Rigel Pharmaceuticals, Inc. 2,3-(hetero)aryl substituted pyridinyl compounds and their use as gdf-8 inhibitors
JP6325449B2 (ja) 2012-10-12 2018-05-16 武田薬品工業株式会社 シクロプロパンアミン化合物およびその用途
US9757379B2 (en) 2012-11-14 2017-09-12 The Board Of Regents Of The University Of Texas System Inhibition of HIF-2α heterodimerization with HIF1β (ARNT)
JP6238908B2 (ja) 2012-11-28 2017-11-29 京都府公立大学法人 リシン構造を有するｌｓｄ１選択的阻害薬
US9144555B2 (en) 2012-11-30 2015-09-29 Darlene E. McCord Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition
EP2740474A1 (en) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN103054869A (zh) 2013-01-18 2013-04-24 郑州大学 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用
CN103933036B (zh) 2013-01-23 2017-10-13 中国人民解放军军事医学科学院毒物药物研究所 2‑芳基咪唑并[1,2‑α]吡啶‑3‑乙酰胺衍生物在制备防治PTSD的药物中的用途
EP2956441A4 (en) 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
WO2014164867A1 (en) 2013-03-11 2014-10-09 Imago Biosciences Kdm1a inhibitors for the treatment of disease
AU2014231768A1 (en) 2013-03-13 2015-09-24 Australian Nuclear Science And Technology Organisation Transgenic non-human organisms with non-functional TSPO genes
AU2014236348B2 (en) 2013-03-14 2018-05-10 Epizyme, Inc. Combination therapy for treating cancer
US20140343118A1 (en) 2013-03-14 2014-11-20 Duke University Methods of treatment using arylcyclopropylamine compounds
EP3003301B1 (en) 2013-05-30 2021-02-24 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells
SG11201510376QA (en) 2013-06-19 2016-01-28 Univ Utah Res Found Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
US9186391B2 (en) 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
WO2015031564A2 (en) 2013-08-30 2015-03-05 University Of Utah Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors
KR101568724B1 (ko) 2013-11-13 2015-11-12 서울대학교산학협력단 신규한 화합물, 이의 생산 방법, 및 히스톤 디메틸라제 저해제로서 이의 용도
EP4257591A3 (en) 2013-12-11 2023-11-22 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
HUE045725T2 (hu) 2014-02-13 2020-01-28 Incyte Corp Ciklopropilaminok mint LSD1 inhibitorok
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
CN103893163B (zh) 2014-03-28 2016-02-03 中国药科大学 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用
US9902722B2 (en) 2014-04-02 2018-02-27 Bristol-Myers Squibb Company Biaryl kinase inhibitors
CN106459024B (zh) 2014-04-11 2019-11-05 武田药品工业株式会社 环丙胺化合物及其用途
CN103961340B (zh) 2014-04-30 2019-06-25 南通中国科学院海洋研究所海洋科学与技术研究发展中心 一类lsd1抑制剂及其应用
EP3148974B1 (en) 2014-05-30 2018-09-26 Istituto Europeo di Oncologia S.r.l. Cyclopropylamine compounds as histone demethylase inhibitors
CN104119280B (zh) 2014-06-27 2016-03-16 郑州大学 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
EA035185B1 (ru) 2014-10-08 2020-05-12 Ф. Хоффманн-Ля Рош Аг Производные спиродиамина в качестве ингибиторов альдостеронсинтазы
CA2980395A1 (en) 2015-04-03 2016-10-06 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
MA51438A (fr) 2015-04-03 2021-04-14 Incyte Corp Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
UY36601A (es) 2015-04-03 2016-09-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Inhibidores de la función enzimática de la indolamina-2,3-dioxigenasa (ido) y composiciones farmacéuticas que los contienen
MX2018001706A (es) 2015-08-12 2018-09-06 Incyte Corp Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
JPWO2017130933A1 (ja) 2016-01-25 2018-11-29 国立大学法人 熊本大学 神経変性疾患治療剤
CN109414410B (zh) 2016-04-22 2022-08-12 因赛特公司 Lsd1抑制剂的制剂
BR112019014759A2 (pt) 2017-01-18 2020-03-03 Vanderbilt University Compostos heterocíclicos fundidos como inibidores seletivos de bmp
MX2019010354A (es) 2017-03-16 2019-10-22 Jiangsu Hengrui Medicine Co Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.

Also Published As

Publication number Publication date
US9695180B2 (en) 2017-07-04
US10556908B2 (en) 2020-02-11
TW201613925A (en) 2016-04-16
US20170369497A1 (en) 2017-12-28
US20190106426A1 (en) 2019-04-11
US20160009720A1 (en) 2016-01-14
US10112950B2 (en) 2018-10-30
WO2016007736A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
AR101174A1 (es) Imidazopirazinas como inhibidores de lsd1
AR101175A1 (es) Imidazopiridinas e imidazopirazinas como inhibidores de lsd1
AR097431A1 (es) Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
CY1121231T1 (el) Παραγωγο τετραϋδροϊμιδαζο[1,5-d][1,4]οξαζεπινης
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
AR095347A1 (es) Compuestos orgánicos
AR095885A1 (es) Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX371353B (es) Compuestos heterociclicos aromaticos como compuestos antiinflamatorios.
AR100160A1 (es) 1H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS Y PIRAZOLO[3,4-c]PIRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEÍNAS BET
RS54840B1 (sr) 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido(2,3-d)pirimidin-6-il)fenil)urea kao inhibitor raf kinaze za tretman kancera
AR091424A1 (es) Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr)
MY177574A (en) New octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors
DK3418281T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
MY194307A (en) Pyridone derivative having tetrahydropyranylmethyl group
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
EA201400338A1 (ru) Производные аминопиримидина для применения в качестве модуляторов киназной активности
MX2015012629A (es) Compuestos de imidazo piridina.
AR105668A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
PE20160201A1 (es) Bencil-1h-pirazol[3,4-b]piridinas y su uso
AR088320A1 (es) Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt

Legal Events

Date Code Title Description
FB Suspension of granting procedure